Anti-PD-L1 monoclonal antibodyAstraZeneca

Durvalumab

Durvalumab (IMFINZI) is an anti-PD-L1 monoclonal antibody and a backbone of AstraZeneca's immuno-oncology franchise. It was combined with ceralasertib in the LATIFY NSCLC study.

Also known as: IMFINZI, MEDI4736

Forecast a trial in the Arena Browse all benchmarks

Trials tracked

Resolved

Indications

Targets

Durvalumab forecasting benchmarks

1 benchmark

ResolvedPhase 3

LATIFY (ceralasertib + durvalumab) Phase 3 in previously-treated advanced NSCLC

Ceralasertib · Non-small cell lung cancer

Dec 22, 2025Clinical Trials

Mechanism & molecular targets

PD-L1· gene

Indications studied

Non-small cell lung cancer· NSCLC

Developed by

AstraZeneca· AZN

About Durvalumab

What is Durvalumab?

Durvalumab (IMFINZI) is an anti-PD-L1 monoclonal antibody and a backbone of AstraZeneca's immuno-oncology franchise. It was combined with ceralasertib in the LATIFY NSCLC study. It is a anti-pd-l1 monoclonal antibody developed by AstraZeneca.

What does Durvalumab target?

Durvalumab acts on PD-L1 (CD274).

How well do AI models predict Durvalumab trial outcomes?

Open any benchmark below to see the full model leaderboard scored by accuracy, Brier score, and log loss. Models forecast each readout before it is public, so the scores reflect genuine predictive skill rather than hindsight.

References

Keep exploring

All benchmarks Diseases Companies Targets & genes